MCID: PLM014
MIFTS: 50

Pleomorphic Adenoma

Categories: Cancer diseases, Gastrointestinal diseases, Endocrine diseases

Aliases & Classifications for Pleomorphic Adenoma

MalaCards integrated aliases for Pleomorphic Adenoma:

Name: Pleomorphic Adenoma 12 14
Mixed Tumor, Not Otherwise Specified 69
Mixed Tumor of the Salivary Gland 12
Mixed Salivary Gland Tumor 69
Adenoma, Pleomorphic 42
Adenoma Pleomorphic 52

Classifications:



External Ids:

Disease Ontology 12 DOID:452
MeSH 42 D008949
NCIt 47 C35691 C8602
SNOMED-CT 64 8360001
UMLS 69 C0026277

Summaries for Pleomorphic Adenoma

Disease Ontology : 12 A gastrointestinal benign neoplasm that is a located in the salivary glands.

MalaCards based summary : Pleomorphic Adenoma, also known as mixed tumor, not otherwise specified, is related to mesenchymoma and pleomorphic adenoma carcinoma. An important gene associated with Pleomorphic Adenoma is PLAG1 (PLAG1 Zinc Finger), and among its related pathways/superpathways are DNA Damage and Development ERBB-family signaling. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, uterus and prostate, and related phenotypes are Increased shRNA abundance (Z-score > 2) and cellular

Wikipedia : 72 Pleomorphic adenoma is a common benign salivary gland neoplasm characterised by neoplastic proliferation... more...

Related Diseases for Pleomorphic Adenoma

Diseases related to Pleomorphic Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 262)
id Related Disease Score Top Affiliating Genes
1 mesenchymoma 30.0 MUC1 TP63 VIM
2 pleomorphic adenoma carcinoma 12.0
3 adenoma 11.1
4 mixed lacrimal gland cancer 11.1
5 adenomas, salivary gland pleomorphic, somatic 10.9
6 2q31.1 microdeletion syndrome 10.9 MUC1 VIM
7 pancoast tumor 10.9 GFAP TP53
8 brain stem astrocytic neoplasm 10.9 GFAP TP53
9 immune-mediated encephalomyelitis 10.9 S100B VIM
10 intellectual disability-polydactyly-uncombable hair syndrome 10.8 GFAP VIM
11 renal pelvis urothelial papilloma 10.8 GFAP TP53
12 tendon sheath lipoma 10.8 GFAP TP53
13 benallegue lacete syndrome 10.8 S100B VIM
14 logopenic progressive aphasia 10.8 MUC1 S100B
15 heiner syndrome 10.8 MUC1 S100B
16 neurogenic thoracic outlet syndrome 10.8 S100B VIM
17 basosquamous carcinoma 10.8 GFAP VIM
18 dedifferentiated liposarcoma 10.8 MUC1 S100B
19 myeloid/lymphoid neoplasm associated with pdgfra rearrangement 10.8 MUC1 VIM
20 ovarian mucinous cystadenofibroma 10.8 GFAP S100B
21 simple cryoglobulinemia 10.7 MUC1 S100B
22 hypogonadotropic hypogonadism-retinitis pigmentosa syndrome 10.7 GFAP TP53
23 mannose-binding lectin protein deficiency 10.7 MUC1 VIM
24 brain glioma 10.7 GFAP TP53
25 vulvar angiokeratoma 10.7 MUC1 VIM
26 congenital disorder of glycosylation, type if 10.7 ERBB2 TP53
27 enteric pattern testicular yolk sac tumor 10.7 MUC1 S100B
28 endocervicitis 10.7 ERBB2 TP53
29 lymphocytic hypophysitis 10.7 ACTC1 VIM
30 aggressive systemic mastocytosis 10.7 GFAP TP53 VIM
31 mycobacterium tuberculosis 2 10.7 HMGA2 PLAG1 S100B
32 gastric signet ring cell adenocarcinoma 10.7 ACTC1 VIM
33 rh isoimmunization 10.7 GFAP TP53
34 skin glomus tumor 10.6 GFAP S100B VIM
35 aortic aneurysm 10.6 ACTC1 VIM
36 adenofibroma 10.6 GFAP S100B
37 anaplastic plasmacytoma 10.6 ACTC1 GFAP
38 iodine hypothyroidism 10.6 GFAP TP53
39 iridogoniodysgenesis and skeletal anomalies 10.6 ACTC1 VIM
40 pyoderma 10.6 GFAP MUC1 VIM
41 spastic ataxia 3 10.6 MUC1 TP53 VIM
42 bladder colloid adenocarcinoma 10.6 MUC1 VIM
43 subglottis verrucous carcinoma 10.6 ERBB2 MUC1
44 noninvasive malignant thymoma 10.6 MUC1 S100B VIM
45 sternum cancer 10.6 GFAP S100B TP53
46 pancreatic intraductal papillary-colloid carcinoma 10.6 MUC1 S100B VIM
47 lice infestation 10.6 MUC1 S100B VIM
48 male reproductive organ benign neoplasm 10.6 HMGA2 PLAG1 TP53
49 hypoglossal nerve neoplasm 10.6 GFAP S100B VIM
50 meningitis and encephalitis 10.6 GFAP MUC1 S100B

Graphical network of the top 20 diseases related to Pleomorphic Adenoma:



Diseases related to Pleomorphic Adenoma

Symptoms & Phenotypes for Pleomorphic Adenoma

GenomeRNAi Phenotypes related to Pleomorphic Adenoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.84 S100B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.84 VIM
3 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.84 PLAGL2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.84 PLAG1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.84 PLAGL2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.84 PLAGL2 VIM
7 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.84 PLAG1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.84 ERBB2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.84 ERBB2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.84 ERBB2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.84 VIM
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.84 VIM
13 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.84 VIM
14 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.84 VIM
15 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.84 ERBB2 PLAG1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.84 PLAGL2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.84 VIM
18 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.84 VIM
19 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.84 ERBB2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.84 PLAG1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.84 PLAGL2 S100B VIM ERBB2 PLAG1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.84 PLAGL2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.84 PLAGL2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.84 S100B VIM ERBB2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.84 PLAG1

MGI Mouse Phenotypes related to Pleomorphic Adenoma:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.26 GFAP KRT14 MDM2 PLAGL1 SERPINB5 TP53
2 growth/size/body region MP:0005378 10.23 KRT14 MDM2 PLAG1 PLAGL1 PLAGL2 SERPINB5
3 cardiovascular system MP:0005385 10.19 ACTC1 AR ERBB2 GFAP MDM2 PLAGL1
4 homeostasis/metabolism MP:0005376 10.17 ACTC1 AR ERBB2 GFAP KRT14 MDM2
5 embryo MP:0005380 10.13 AR ERBB2 MDM2 PLAG1 PLAGL1 SERPINB5
6 digestive/alimentary MP:0005381 10.1 AR ERBB2 GFAP KRT14 MDM2 PLAGL2
7 mortality/aging MP:0010768 10.1 VIM ACTC1 AR ERBB2 GFAP KRT14
8 integument MP:0010771 10.01 AR ERBB2 KRT14 MDM2 PLAGL1 S100B
9 craniofacial MP:0005382 9.99 AR ERBB2 KRT14 MDM2 TP53 TP63
10 muscle MP:0005369 9.86 VIM ACTC1 AR ERBB2 GFAP MDM2
11 limbs/digits/tail MP:0005371 9.85 AR ERBB2 MDM2 PLAGL1 TP53 TP63
12 neoplasm MP:0002006 9.63 AR ERBB2 KRT14 MDM2 TP53 TP63
13 normal MP:0002873 9.61 ACTC1 AR ERBB2 GFAP MDM2 S100B
14 reproductive system MP:0005389 9.23 AR ERBB2 KRT14 MDM2 PLAG1 TP53

Drugs & Therapeutics for Pleomorphic Adenoma

Drugs for Pleomorphic Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 75)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
4
Mechlorethamine Approved Phase 3,Phase 2 51-75-2 4033
5 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
6 Antimitotic Agents Phase 3,Phase 2,Phase 1
7 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
8 Alkylating Agents Phase 3,Phase 2
9 Isophosphamide mustard Phase 3,Phase 2
10
Gemcitabine Approved Phase 2 95058-81-4 60750
11
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
12
Mesna Approved Phase 2 3375-50-6 598
13
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
14
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
15
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
16
Cisplatin Approved Phase 2,Phase 1 15663-27-1 84093 441203 2767
17
Everolimus Approved Phase 2 159351-69-6 6442177
18
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
19
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
20
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
21
Metformin Approved Phase 2 657-24-9 14219 4091
22
nivolumab Approved Phase 2 946414-94-4
23
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
24
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
25
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
26
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
27
Nicotinamide Approved, Nutraceutical Phase 2 98-92-0 936
28
Doxil Approved June 1999 Phase 2 31703
29
Docetaxel Approved May 1996, Investigational Phase 2,Phase 1 114977-28-5 148124 9877265
30
Saracatinib Investigational Phase 2 379231-04-6
31
Tremelimumab Investigational Phase 2 745013-59-6
32 Anti-Infective Agents Phase 2
33 Antimetabolites Phase 2,Phase 1
34 Antimetabolites, Antineoplastic Phase 2,Phase 1
35 Antiviral Agents Phase 2
36 Immunosuppressive Agents Phase 2,Phase 1
37 Protein Kinase Inhibitors Phase 2,Phase 1
38 Epothilones Phase 2,Phase 1
39 Anti-Bacterial Agents Phase 2
40 Antibiotics, Antitubercular Phase 2
41 Topoisomerase Inhibitors Phase 2
42
iniparib Phase 2
43 Poly(ADP-ribose) Polymerase Inhibitors Phase 2,Phase 1
44 Imatinib Mesylate Phase 2 123596
45 Angiogenesis Inhibitors Phase 2,Phase 1
46 Angiogenesis Modulating Agents Phase 2,Phase 1
47 Micronutrients Phase 2
48 Nicotinic Acids Phase 2
49 Trace Elements Phase 2
50 Vitamin B Complex Phase 2

Interventional clinical trials:

(show all 49)

id Name Status NCT ID Phase Drugs
1 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
2 Quadrant Versus Superficial Parotidectomy Withdrawn NCT01607866 Phase 2, Phase 3
3 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Unknown status NCT02203760 Phase 2 Pazopanib plus Gemcitabine;Pazopanib
4 Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus Completed NCT00502203 Phase 2 Carboplatin;Paclitaxel
5 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2 gemcitabine
6 Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours Completed NCT00189410 Phase 2 Pegylated Liposomal Doxorubicin and Carboplatin
7 A Phase II Trial of Adjuvant Radiation Therapy With Ifosfamide in Patients With MMT of the Uterus Completed NCT00231842 Phase 2 Ifosfamide
8 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
9 Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus Completed NCT00476086 Phase 2 Gemcitabine;Oxaliplatin
10 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
11 Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00687687 Phase 2 paclitaxel;carboplatin;BSI-201 (Iniparib)
12 Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
13 Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00075400 Phase 2 imatinib mesylate
14 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
15 Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer Completed NCT00238121 Phase 2 sorafenib tosylate
16 Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors Completed NCT00520013 Phase 2 bevacizumab;erlotinib;paclitaxel;carboplatin
17 Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer Completed NCT00511992 Phase 2 Avastin;Paclitaxel;Cisplatin
18 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
19 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
20 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
21 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2 ziv-aflibercept
22 A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Recruiting NCT03015129 Phase 2 Durvalumab;Tremelimumab
23 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
24 A Study of Nivolumab in Selected Uterine Cancer Patients Recruiting NCT03241745 Phase 2 Nivolumab
25 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
26 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT02101775 Phase 2 Gemcitabine Hydrochloride;WEE1 Inhibitor AZD1775
27 Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer Active, not recruiting NCT01168232 Phase 2 ixabepilone
28 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT00478426 Phase 2 Sunitinib Malate
29 Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)_MITO 26 Not yet recruiting NCT02993705 Phase 2 Trabectedin
30 Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Suspended NCT01935934 Phase 2 Cabozantinib S-malate
31 Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer Terminated NCT00322881 Phase 2 Paclitaxel;Carboplatin
32 Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy Terminated NCT00505492 Phase 2 Carboplatin;Cisplatin;Paclitaxel
33 Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus Terminated NCT01061606 Phase 2 temsirolimus
34 Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies Withdrawn NCT00984217 Phase 2 Panitumumab
35 A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma Unknown status NCT01454479 Phase 1 Lapatinib and ixempra
36 Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors Completed NCT00413322 Phase 1 belinostat;5-Fluorouracil (5-FU)
37 Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma Completed NCT00413075 Phase 1 oral belinostat
38 Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer Completed NCT00352300 Phase 1 Carboplatin;Paclitaxel
39 Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) Completed NCT00085358 Phase 1 carboplatin;paclitaxel;docetaxel
40 Suitability of DCE-MRI for Detection of Vascular Changes After VBT Recruiting NCT01991808 Phase 1
41 Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary Recruiting NCT03206177 Phase 1 Galunisertib;Paclitaxel;Carboplatin
42 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
43 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Suspended NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
44 Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer Unknown status NCT01367301 paclitaxel;carboplatin
45 Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer Recruiting NCT02983279
46 Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Active, not recruiting NCT01080521
47 Study of Imaging Characteristics OCT of Skin Lesions Requiring Biopsy / Resection Not yet recruiting NCT02851693
48 microRNA Profiles Identification in Adeno Carcinoma Prostate Cancer Not yet recruiting NCT02964351
49 Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient No longer available NCT02090127 ficlatuzumab

Search NIH Clinical Center for Pleomorphic Adenoma

Cochrane evidence based reviews: adenoma, pleomorphic

Genetic Tests for Pleomorphic Adenoma

Anatomical Context for Pleomorphic Adenoma

MalaCards organs/tissues related to Pleomorphic Adenoma:

39
Salivary Gland, Uterus, Prostate, Liver, Trachea, Bone, Skin

Publications for Pleomorphic Adenoma

Articles related to Pleomorphic Adenoma:

(show top 50) (show all 784)
id Title Authors Year
1
The Effects of Platelet-Rich Fibrin Membrane on Secondary Healing After Pleomorphic Adenoma Excision in the Hard Palate: A Preliminary Study. ( 28713740 )
2017
2
Re: Endoscopically-assisted extracapsular dissection of pleomorphic adenoma of the parotid gland through a postauricular sulcus approach in young patients. ( 28735635 )
2017
3
Clinicopathologic and Surgical Study of Pleomorphic Adenoma of the Parotid Gland: Analysis of Risk Factors for Recurrence and Facial Nerve Dysfunction. ( 28863883 )
2017
4
Metastasizing pleomorphic adenoma of the parotid gland. ( 28900471 )
2017
5
Pleomorphic adenoma gene like-2 induces epithelial-mesenchymal transition via Wnt/I^-catenin signaling pathway in human colorectal adenocarcinoma. ( 28259923 )
2017
6
Synchronous contralateral pleomorphic adenoma of the parotid gland and submandibular gland. ( 27914682 )
2017
7
Low Grade Carcinoma Ex-Pleomorphic Adenoma: Diagnosis and Diagnostic Challenges Caused by Fine Needle Aspiration: Report of Three Cases and Review of Literature. ( 28589437 )
2017
8
Diffusion-weighted MRI for differentiation between sialadenitis and pleomorphic adenoma. ( 27845594 )
2017
9
Pleomorphic Adenoma of an Accessory Lacrimal Gland Masquerading as a Chalazion. ( 28645342 )
2017
10
Giant Parapharyngeal Space Pleomorphic Adenoma Causing Acute Airway Obstruction. ( 28584606 )
2017
11
Hemifacial Spasm Secondary to Parotid Pleomorphic Adenoma With Stylomastoid Foramen Extension. ( 27755360 )
2017
12
Largest De Novo Parapharyngeal Pleomorphic Adenoma: A Rare Case Removed Via Minimal Access Approach. ( 28713752 )
2017
13
Parapharyngeal space pleomorphic adenoma: a case report. ( 28690748 )
2017
14
A Case Report of Rare Carcinoma Ex Pleomorphic Adenoma of Submandibular Gland and its Detailed Description. ( 28658924 )
2017
15
Increased SOX2 expression in salivary gland carcinoma ex pleomorphic adenoma progression: an association with adverse outcome. ( 28842747 )
2017
16
Carcinoma ex pleomorphic adenoma: case report and options for systemic therapy. ( 28680294 )
2017
17
Transnasal Endoscopic Resection of a Pleomorphic Adenoma Originate From Nasal Floor. ( 28857999 )
2017
18
The role of insulin-like growth factor I-II receptor on development of pleomorphic adenoma. ( 28625007 )
2017
19
Circulating high mobility group AT-hook 2 and pleomorphic adenoma gene 1 in blood of patients with oral squamous cell carcinoma. ( 28650082 )
2017
20
Solitary fibrous tumor of the lacrimal gland mimicking pleomorphic adenoma. ( 28832740 )
2017
21
PLAG1 immunohistochemistry is a sensitive marker for Pleomorphic Adenoma: a comparative study with PLAG1 genetic abnormalities. ( 28796899 )
2017
22
Prognostic nomogram for disease-specific survival of carcinoma ex pleomorphic adenoma of the salivary gland. ( 28945292 )
2017
23
Volumetric Growth Rate of Recurrent Pleomorphic Adenoma. ( 28604082 )
2017
24
Unusual Pleomorphic Adenoma of the Lacrimal Gland: Immunohistochemical Demonstration of PLAG1 and HMGA2 Oncoproteins. ( 27567603 )
2016
25
Pleomorphic Adenoma of Minor Salivary Gland Arising de novo in the Parapharyngeal Space- A Rare Case Report. ( 27135010 )
2016
26
Carcinoma Ex Pleomorphic Adenoma of the Tongue: Difficulty in Diagnosis Between Metastasis of Breast Cancer and Salivary Tumor. ( 27755404 )
2016
27
Electrical stimulation treatment for facial palsy after revision pleomorphic adenoma surgery. ( 27106613 )
2016
28
Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations. ( 27379604 )
2016
29
Differing Lymphatic Vessels Density in Salivary Adenoid Cystic Carcinoma and Pleomorphic Adenoma. ( 27837476 )
2016
30
Pleomorphic adenoma involving soft tissue overlying the anterior border of ramus of the mandible: A rare ectopic presentation. ( 27900254 )
2016
31
A rare carcinoma ex pleomorphic adenoma of the buccal minor salivary gland causing a therapeutic dilemma. ( 27146731 )
2016
32
Pleomorphic adenoma of the larynx. ( 28058389 )
2016
33
Comparison of functional change in parotid gland after surgical excision of pleomorphic adenoma by two different types of parotidectomy. ( 27492567 )
2016
34
Prognostic factors of carcinoma ex pleomorphic adenoma of the salivary glands, with emphasis on the widely invasive carcinoma: a clinicopathologic analysis of 361 cases in a Chinese population. ( 27546212 )
2016
35
Rare Primary Pleomorphic Adenoma in Posterior Fossa. ( 27465421 )
2016
36
Pleomorphic Adenoma of the Eyelid with Apocrine Gland Origin; an Atypical Location. ( 27994815 )
2016
37
MYB expression: Potential role in separating adenoid cystic carcinoma (ACC) from pleomorphic adenoma (PA). ( 27491495 )
2016
38
Comparison of Frey Syndrome Rates Following Superficial Parotidectomy and Partial Superficial Parotidectomy for Pleomorphic Adenoma. ( 27391515 )
2016
39
Diagnosis of a rapidly growing preauricular nodule: chondroid syringoma or pleomorphic adenoma? ( 27874890 )
2016
40
Twist Expression in Pleomorphic Adenoma, Adenoid Cystic Carcinoma and Mucoepidermoid Carcinoma of Salivary Glands. ( 26832177 )
2016
41
Oncocytic Pleomorphic Adenoma of Palatal Salivary Gland with Macrophages and Giant Cells Associated with Cholesterol Crystals. ( 28028431 )
2016
42
Metastasizing pleomorphic adenoma in cavernous sinus: letter to the editor. ( 26917421 )
2016
43
Pleomorphic adenoma in the nasal cavity: a clinicopathological study of ten cases in Finland. ( 27056196 )
2016
44
Giant pleomorphic adenoma of the parotid gland. ( 27061390 )
2016
45
PLAG1 expression is maintained in recurrent pleomorphic adenoma. ( 27381214 )
2016
46
Carcinoma Ex Pleomorphic Adenoma: Is It a High-Grade Malignancy? ( 27131030 )
2016
47
Carcinoma Ex Pleomorphic Adenoma of the Lacrimal Gland with Epithelial-Myoepithelial Carcinoma Histologic Type. ( 26934566 )
2016
48
Endobronchial pleomorphic adenoma. ( 28031854 )
2016
49
The relationship between proteoglycan inhibition via xylosyltransferase II silencing and the implantation of salivary pleomorphic adenoma. ( 27732748 )
2016
50
Clinico-radiological features of primary lacrimal gland pleomorphic adenoma: an analysis of 37 cases. ( 27184391 )
2016

Variations for Pleomorphic Adenoma

Cosmic variations for Pleomorphic Adenoma:

9 (show all 13)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10808 TP53 salivary gland,parotid,adenoma,pleomorphic c.488A>G p.Y163C 14
2 COSM43909 TP53 salivary gland,parotid,adenoma,pleomorphic c.817C>A p.R273S 14
3 COSM43878 TP53 salivary gland,NS,adenoma,pleomorphic c.427G>A p.V143M 13
4 COSM44733 TP53 salivary gland,NS,adenoma,pleomorphic c.698A>C p.H233P 13
5 COSM533 KRAS salivary gland,NS,adenoma,pleomorphic c.38G>C p.G13A 13
6 COSM482 HRAS salivary gland,NS,adenoma,pleomorphic c.34G>C p.G12R 13
7 COSM480 HRAS salivary gland,NS,adenoma,pleomorphic c.34G>A p.G12S 13
8 COSM486 HRAS salivary gland,NS,adenoma,pleomorphic c.37G>C p.G13R 13
9 COSM6932 TP53 salivary gland,parotid,adenoma,myoepithelial c.733G>A p.G245S 10
10 COSM43635 TP53 salivary gland,parotid,adenoma,myoepithelial c.536A>T p.H179L 10
11 COSM13168 CTNNB1 salivary gland,parotid,adenoma,NS c.104T>C p.I35T 9
12 COSM5688 CTNNB1 salivary gland,parotid,adenoma,NS c.121A>C p.T41P 9
13 COSM21826 ATM salivary gland,parotid,adenoma,NS c.2572T>C p.F858L 9

Copy number variations for Pleomorphic Adenoma from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 239266 8 38279166 38315052 Gain FGFR1 Pleomorphic adenoma

Expression for Pleomorphic Adenoma

Search GEO for disease gene expression data for Pleomorphic Adenoma.

Pathways for Pleomorphic Adenoma

GO Terms for Pleomorphic Adenoma

Cellular components related to Pleomorphic Adenoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nuclear chromatin GO:0000790 8.92 AR MUC1 TP53 TP63

Biological processes related to Pleomorphic Adenoma according to GeneCards Suite gene sharing:

(show all 20)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.95 AR HMGA2 PLAG1 PLAGL1 PLAGL2 TP53
2 negative regulation of apoptotic process GO:0043066 9.92 ACTC1 HMGA2 MDM2 TP53 TP63
3 cellular response to hypoxia GO:0071456 9.74 MDM2 S100B TP53
4 apoptotic process GO:0006915 9.73 ACTC1 PLAGL1 TP53 TP63
5 transcription from RNA polymerase II promoter GO:0006366 9.73 HMGA2 PLAG1 PLAGL1 PLAGL2 TP53 TP63
6 epithelial cell differentiation GO:0030855 9.69 KRT14 MUC1 TP63
7 prostate gland development GO:0030850 9.58 AR TP63
8 positive regulation of transcription from RNA polymerase III promoter GO:0045945 9.56 AR ERBB2
9 mitotic G1 DNA damage checkpoint GO:0031571 9.54 TP53 TP63
10 prostate gland growth GO:0060736 9.48 AR PLAG1
11 negative regulation of neuron projection development GO:0010977 9.46 MDM2 VIM
12 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.33 MUC1 TP53 TP63
13 cellular response to actinomycin D GO:0072717 9.32 MDM2 TP53
14 intermediate filament organization GO:0045109 9.29 VIM
15 astrocyte development GO:0014002 9.28 VIM
16 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.26 MDM2 MUC1 PLAGL1 TP53
17 positive regulation of glial cell proliferation GO:0060252 9.25 PLAG1
18 positive regulation of gene expression GO:0010628 9.23 ACTC1 AR ERBB2 HMGA2 MDM2 PLAG1
19 Bergmann glial cell differentiation GO:0060020 9.19 VIM
20 intermediate filament-based process GO:0045103 9.07 VIM

Molecular functions related to Pleomorphic Adenoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription factor activity, sequence-specific DNA binding GO:0003700 9.8 AR PLAG1 PLAGL1 PLAGL2 TP53 TP63
2 structural constituent of cytoskeleton GO:0005200 9.58 GFAP KRT14 VIM
3 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001077 9.55 AR HMGA2 PLAG1 PLAGL2 TP63
4 identical protein binding GO:0042802 9.5 ERBB2 GFAP MDM2 S100B TP53 TP63
5 transcription factor activity, transcription factor binding GO:0000989 9.37 HMGA2 TP63
6 keratin filament binding GO:1990254 9.26 KRT14 VIM
7 p53 binding GO:0002039 8.92 MDM2 MUC1 TP53 TP63

Sources for Pleomorphic Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....